Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Consensus Recommendation of “Buy” from Analysts

Avalyn Pharma Inc. (NASDAQ:AVLN) has earned an average recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $59.00.

AVLN has been the topic of a number of research analyst reports. Morgan Stanley began coverage on shares of Avalyn Pharma in a research report on Tuesday. They set an “overweight” rating and a $53.00 price objective on the stock. Evercore began coverage on shares of Avalyn Pharma in a research report on Tuesday. They issued an “outperform” rating and a $51.00 price target on the stock. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday. Finally, Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research report on Monday. They issued a “buy” rating and a $52.00 price target on the stock.

Avalyn Pharma Stock Up 5.9%

AVLN stock opened at $28.39 on Friday. Avalyn Pharma has a 1 year low of $25.05 and a 1 year high of $32.22.

Insider Activity

In other Avalyn Pharma news, Director Jill Carroll purchased 277,778 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were acquired at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director owned 2,186,562 shares in the company, valued at $39,358,116. The trade was a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the transaction, the insider owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 34.06% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.